Rivaroxaban
Evidence-based neurology checklist on rivaroxaban: Characteristics Rivaroxaban is a factor Xa inhibitor It has a rapid onset of action It is non-inferior to warfarin Its excretion is 2/3 hepatic and 1/3 renal Dose Contrindications Recommendations in stroke Interactions Complications Switching to…
Characteristics
- Rivaroxaban is a factor Xa inhibitor
- It has a rapid onset of action
- It is non-inferior to warfarin
- Its excretion is 2/3 hepatic and 1/3 renal
Dose
Contrindications
Recommendations in stroke
Interactions
Complications
Switching to Warfarin from Rivaroxaban
Switching from Warfarin to Rivaroxaban
Management of bleeding: Andexanet alfa
Management of bleeding: other measures
References
- Steffel J, Braunwald E. Novel oral anticoagulants: focus on stroke prevention and treatment if venous thrombo-embolism. Eur Heart J 2011; 32:1968-1976.
- Tendera M, Syzdol M, Parma Z. ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation? Cardiol J 2012; 19:4-10.
- Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891.
- Haas S, Bode C, Norrving B, Turpie AG. Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. Vasc Health Risk Manag 2014; 10:101-114.
- Carpenter E, Singh D, Dietrich E, Gums J. Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation. Ther Adv Drug Saf 2019; 10:2042098619888133.
- And 1 more. Subscribe to see the full list
